The QualityStocks Daily Friday, March 10th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(CZOO) $2.6200 +32.32%

MarketClub Analysis(UNCY) $2.6800 +30.10%

SmallCapRelations(KSCP) $1.0300 +18.39%

The QualityStocks Daily Stock List

Cazoo Group (CZOO)

MarketBeat and QualityStocks reported earlier on Cazoo Group (CZOO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cazoo Group Ltd (NYSE: CZOO) (FRA: 8QE0) is an online car retail firm that provides a platform which allows consumers to purchase used vehicles online.

The firm has its headquarters in London, the United Kingdom and was incorporated in 2018 by Alexander Edward Chesterman. Prior to its name change, the firm was known as Capri Listco. The firm mainly serves consumers in the United Kingdom and Europe.

The company is focused on transforming the car purchasing experience across Europe and the UK. Its objective is to make the experience of purchasing a car easy, transparent and convenient. It does so by allowing consumers to seamlessly finance, purchase or subscribe to a vehicle entirely online for either collection or delivery, in 72 hours.

The enterprise offers a range of hatchbacks and sport utility vehicles, which include different hybrid and electric vehicles. Its portfolio of cars includes Fiat, Skoda, Volkswagen, Nissan, Mercedes-Benz, Land Rover, Ford, BMW and Audi. The enterprise also provides car care services, including paint and fabric protection and extended warranty. Its Paint and Fabric protection includes paintwork fading and protection from pollution, among others. Its extended warranty offers cover for electrical and mechanical parts, including clutch and air conditioning, automatic and manual gearbox, diesel particulate filter, engine, cooling system, steering, suspension and braking system.

The company is focused on its continued growth and expansion in Europe and the UK. It plans to capitalize on opportunities that allow them to deliver the best car selling and purchasing experience for consumers, which will be good for its revenues as well as its investments.

Cazoo Group (CZOO), closed Friday's trading session at $2.62, up 32.3232%, on 5,256,822 volume. The average volume for the last 3 months is 31.611M and the stock's 52-week low/high is $1.93/$65.20.

Tenax Therapeutics (TENX)

QualityStocks, TraderPower, StockMarketWatch, BUYINS.NET, TradersPro, Schaeffer's, StocksImpossible, OTCBB Journal, MarketClub Analysis, First Penny Picks, MarketBeat, StreetInsider, The Online Investor, The Stock Dork, PennyStockScholar, PennyStockProphet and RedChip reported earlier on Tenax Therapeutics (TENX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tenax Therapeutics Inc. (NASDAQ: TENX) (FRA: YBOC) is a specialty pharmaceutical firm which is focused on the identification, development and commercialization of products which address unmet medical needs for pulmonary and cardiovascular ailments in Canada and the United States.

The firm has a remarkable scientific advisory team, which includes recognized international experts in pulmonary hypertension. It is based in Morrisville, North Carolina and was incorporated in 1967, on May 26. Before changing its name to Tenax Therapeutics Inc., the firm was known as Oxygen Biotherapeutics Inc.

The company is also engaged in the cosmetic industry and has developed the DERMACYTE line of skin care products, which addresses various common aging issues, including blemishes, skin tone, puffiness, wrinkles, fine lines and more. This is in addition to developing a PFC-based topical cream for use in dermatological indications and wounds.

Additionally, it owns the rights to commercialize and develop levosimendan in North America, which was developed as a pulmonary hypertension treatment associated with preserved ejection fraction and heart failure. Apart from levosimendan, the firm is also engaged in the development of a tyrosine kinase inhibitor indicated for treating pulmonary arterial hypertension, known as Imatinib.

The company recently reported progress in its phase II study of its candidate levosimendan as a treatment for heart failure and pulmonary hypertension. Their statement noted that the drug effectively decreased pulmonary capillary wedge pressure and was the first drug to show improved cardiovascular hemodynamics. Given that pulmonary hypertension and heart failure with preserved ejection fraction has no effective medical treatments, the company’s candidate may well be on its way to becoming the first approved treatment for this disease. This will help address a previously unmet clinical need, which will help patients who suffer from this ailment, while also benefitting the firm and its shareholders.

Tenax Therapeutics (TENX), closed Friday's trading session at $0.5698, up 22.9607%, on 31,610,843 volume. The average volume for the last 3 months is 3,500 and the stock's 52-week low/high is $0.452/$17.00.

Resolute Mining (RMGGF)

QualityStocks, Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on Resolute Mining (RMGGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Resolute Mining Limited (OTC: RMGGF) (ASX: RSG) (LON: RSG) FRA: RSM) is a mining firm engaged in exploring for, developing, operating and producing gold from properties in Australia, Africa and the United Kingdom.

The firm has its headquarters in Perth, Australia and was incorporated in 2001, on June 8th. It operates as part of the gold industry, under the basic materials sector. The firm primarily serves consumers in Australia and Africa.

The enterprise’s portfolio includes the Syama Mine and Mako Gold Mine. The Syama Mine is a robust, long-life asset comprising an underground mine and associated sulfide processing circuit, along with satellite open pit operations which provide ore feed to a separate oxide processing circuit. This mine is located in the south of Mali, West Africa, approximately 32 kilometers from the Cote d’Ivoire border and approximately 300 km southeast of the capital Bamako. It comprises the Syama Underground Mine and the Tabakoroni complex. The Mako Gold Mine is a high quality, open pit gold mine that is located in eastern Senegal, West Africa. The enterprise is also involved in exploration with drilling campaigns underway across its African tenements with a focus on Mali, Senegal, and Guinea. It generates the majority of its revenue from the Syama (Mali) segment.

The company recently announced its latest financial and operational results, which show increases in its revenues as well as higher gold production. It remains focused on increasing gold production, thereby bringing in additional revenues.

Resolute Mining (RMGGF), closed Friday's trading session at $0.1815, even for the day. The average volume for the last 3 months is 15,200 and the stock's 52-week low/high is $0.102717/$0.2718.

Petrus Resources (PTRUF)

We reported earlier on Petrus Resources (PTRUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Petrus Resources Ltd (OTCQX: PTRUF) (TSE: PRQ) (FRA: 6P4) is an energy firm focused on acquiring, exploring for, developing and exploiting oil and gas development assets in western Canada.

The firm has its headquarters in Calgary, Canada and was incorporated in 2015, on November 25th by Donald T. Gray. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers in Canada.

The company focuses on risk-managed exploration, primarily exploring for natural gas, natural gas liquids, and crude oil and condensate. It generates the majority of its revenue from oil and natural gas.

The enterprise's core operating areas are Ferrier, Central Alberta and the Rocky Mountain foothills. It holds an average 51% working interest in the Ferrier/Strachan area, made up of 43,159 net acres, which include 29,219 net acres of undeveloped and 13,940 net acres of developed land located in west central Alberta near the town of Rocky Mountain House, Alberta. It also holds an average of 64% working interest in the Thorsby/Pembina area, comprising of 69,042 net acres of land covering 22,135 net acres of undeveloped land and 46,907 net acres of developed land located in the southwest of Edmonton, Alberta. This is in addition to holding an average of 50% working interest in the Foothills area that is made up of 30,748 net acres of undeveloped land and 6,687 net acres of developed land located northwest of Rocky Mountain House, Alberta.

The firm’s latest update shows increases in its production, which will bring in additional revenues for the firm and help create shareholder value as well.

Petrus Resources (PTRUF), closed Friday's trading session at $1.37, off by 0.594979%, on 15,200 volume. The average volume for the last 3 months is 5,000 and the stock's 52-week low/high is $1.07/$2.68.

Precinct Properties New Zealand (AOTUF)

We reported earlier on Precinct Properties New Zealand (AOTUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Precinct Properties New Zealand Ltd (OTC: AOTUF) (NZE: PCT) is focused on investing in central business district office properties.

The firm has its headquarters in Auckland, New Zealand and was incorporated in 1997, on November 13th. It operates as part of the REIT-Diversified industry, under the real estate sector. The firm primarily serves consumers in New Zealand.

The company is a city center specialist investing predominantly in premium and A-grade commercial office property. It operates through the Investment Properties and Flexible Space segments. The Investment Properties segment involves investment in predominately-prime CBD properties. The Flexible Space segment includes the operation of co-working and shared spaces. It generates maximum revenue from the investment properties segment. The company is managed by AMP Haumi Management Limited.

The enterprise owns Auckland's HSBC Tower, AON Center, Jarden House, Deloitte Center, 204 Quay Street, Mason Bros. Building, 12 Madden Street, 10 Madden Street, PwC Tower and Commercial Bay Retail; and Wellington's AON Center, NTT Tower, Central on Midland Park, No. 1 and No. 3 The Terrace, Mayfair House, Charles Fergusson Building, Defence House, Bowen House and Freyberg Building. It also owns Generator NZ, a premier flexible office space provider. Generator currently offers 13,600 m2 of space across 4 locations in Auckland.

This firm recently announced its latest financial results, which show increases in its revenues. It remains focused on growing its portfolio, which will help generate additional revenues as well as shareholder value.

Precinct Properties New Zealand (AOTUF), closed Friday's trading session at $0.775, even for the day. The average volume for the last 3 months is 237 and the stock's 52-week low/high is $0.65/$1.15.

Anadolu Efes Biracilik Ve Malt Sanayii (AEBZY)

We reported earlier on Anadolu Efes Biracilik Ve Malt Sanayii (AEBZY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Anadolu Efes Biracilik ve Malt Sanayii AS (OTC: AEBZY) (FRA: EF41) (IST: AEFES) is a holding firm that is focused on producing, bottling, distributing and selling beer, malt and non-alcoholic drinks.

The firm has its headquarters in Istanbul, Turkey and was incorporated in 1966, on February 2nd. It operates as part of the beverages-brewers industry, under the consumer defensive sector. The firm serves consumers around the globe, with a focus on those in Turkey.

The company operates as an Efes Beverage Group holding firm. It operates through the Turkey Beer, International Beer, Soft Drinks and Other and Eliminations segments. The Other and Eliminations segment includes other subsidiaries and headquarter expenses included in the consolidation of the Group. The company has joint control over Coca-Cola Icecek, which has the rights to sell Coca-Cola products in Turkey, Central Asia, Pakistan and the Middle East. Sparkling and still beverages make up more than half of the company's total revenue. Beer sales account for the remaining revenue, with beer sales outside of Turkey (mainly in Russia, Kazakhstan, Georgia, and Moldova) collectively providing more revenue than beer sales in Turkey. The company has breweries, bottling plants, and other production facilities in more than a dozen countries, primarily Turkey and Russia.

The enterprise also produces, bottles and distributes fruit juice concentrates, purees and fresh fruit, and carbonated soft drinks under the Coca-Cola Company trademark; and fills of spring water beverages. In addition, it leases intellectual property and related products.

The company remains focused on extending its consumer reach, better meeting consumer needs and generating value for its shareholders.

Anadolu Efes Biracilik Ve Malt Sanayii (AEBZY), closed Friday's trading session at $0.704, even for the day. The average volume for the last 3 months is 50,817 and the stock's 52-week low/high is $0.275/$0.704.

Focus Universal (FCUV)

QualityStocks and The Street reported earlier on Focus Universal (FCUV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Focus Universal Inc. (NASDAQ: FCUV) is a firm focused on the development and manufacture of smart instrumentation platforms and devices.

The Firm has its headquarters in Ontario, Canada and was incorporated in 2012, on December 4th by Desheng Wang. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers around the world.

The enterprise’s offerings include a wireless sensor device dubbed Ubiquitor, which has a universal sensor node and gateway system that uses a computer or mobile device as the output display module that displays the readings of various sensor nodes. Its universal smart instrumentation platform (USIP) uses computers or mobile devices to communicate with smart devices, such as sensors, probes, instruments and controllers to monitor and control any functions. It also provides digital sensors and horticultural sensors. In addition to this, the enterprise offers filter and handheld meter products, including carbon filters, fan speed adjuster and HEPA filtration systems, as well as digital light and quantum parameters through distributors. Furthermore, the enterprise offers integration of houses, apartments, commercial complexes, and office spaces with visual, audio and control systems to integrate devices in the low voltage field, as well as partial equipment upgrade and installation services.

The company, which has 3 foundational patents granted and 13 provisional patents covering a broad spectrum of technologies, remains focused on better meeting evolving consumer needs, bolstering its overall growth and generating value for its shareholders.

Focus Universal (FCUV), closed Friday's trading session at $4.77, off by 16.0211%, on 50,817 volume. The average volume for the last 3 months is 1.139M and the stock's 52-week low/high is $4.69/$16.50.

Stronghold Digital Mining Inc. (SDIG)

QualityStocks, RedChip, MarketBeat, SmallCapVoice, Real Pennies, InvestorPlace, StocksEarning, StockPicksNYC and OTC Markets Group reported earlier on Stronghold Digital Mining Inc. (SDIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Early last year when Russian forces invaded Ukraine, the crypto community was quick to mobilize as donations poured in to help those affected by this unprovoked war. The donations mainly went to government agencies as well as nongovernmental organizations involved in the relief efforts.

Recently several DAOs and crypto projects have shifted their attention to raising funds to help those affected by the earthquakes in Syria and Turkey. These efforts aren’t gaining mainstream media attention due to the preoccupation with the Ukraine war.

Endaoment, an NGO that was launched in 2019, says in the wake of the earthquakes that devastated Syria and Turkey, donations in the form of cryptos started flowing to support efforts to help those most in need in the earthquake-affected area. Endaoment was formed to manage as well encourage the cryptocurrency community to support worthy charitable causes.

Robbie Heeger, CEO and president of Endaoment, observed that the crypto community is passionate about sovereignty and the protection of human rights, so it was almost automatic that the organization would spring into action to support the government in Ukraine as well as the civilians who are resisting the aggression of Russia after the February 2022 invasion. There was hardly any need to explain to members why donations were needed in Ukraine, he added.

However, Heeger points out that the humanitarian crisis in Syria and Turkey hasn’t attracted as much enthusiasm within the crypto community. True, donations are coming in, but they are nowhere near the scale that the Ukraine relief effort attracted. He thinks that this low-level response is partly due to the media paying ore attention to the war in Ukraine, and he also posits that the natural disaster hasn’t aroused as much sentiment because it doesn’t touch on sovereignty and abuse of human rights by a foreign power.

At the core of the blockchain/crypto movement is a strong need to break loose from control by a central authority or government, hence the decentralization of finance. Any cause that can be linked to fighting back against government control or aggression seems to trigger an immediate response within the crypto community.

Notwithstanding, organizations such as Turkey Relief DAO are seeing encouraging responses to their efforts to highlight the different NGOs and agencies working to help those affected by the recent earthquake in Turkey. The funds they raise go directly to these organizations working in the disaster zones. So far, wallets have been established on 18 crypto chains in order to receive donations and channel those funds where aid is most needed.

As entities such as Stronghold Digital Mining Inc. (NASDAQ: SDIG) continue to make it possible for people to earn digital assets, there will always be the added benefit of giving people the ability to chip in to support charitable causes whenever the need arises.

Stronghold Digital Mining Inc. (SDIG), closed Friday's trading session at $0.4515, off by 5.2466%, on 1,139,322 volume. The average volume for the last 3 months is 609,679 and the stock's 52-week low/high is $0.40/$11.14.

Grapefruit USA Inc. (GPFT)

QualityStocks, Stocks to Buy Now, SmallCapRelations, SeriousTraders, NetworkNewsWire, HempWire, CBDWire, CannabisNewsWire, InvestorBrandNetwork, StocksToBuyNow, Kiplinger Today, Pennystockmania and PennyPickGains reported earlier on Grapefruit USA Inc. (GPFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grapefruit USA (OTCQB: GPFT), an innovative California-based cannabiotech company, today provided an update to its recent announcement regarding the proposed acquisition of Diagnostic Lab Corporation Inc. of Englewood Cliffs, New Jersey (“DLC”), a diversified food and agriculture safety company, as well as the proposed recapitalization of the company. “We are providing this update to inform our many loyal shareholders that the company is making significant progress with respect to the DLC acquisition and securing additional capital, despite the challenging current macro-economic environment and its influence on the capital markets. Grapefruit’s management, staff and outside professionals continue to work together very efficiently to ensure a successful acquisition of DLC,” said Bradley J. Yourist, Grapefruit’s CEO and co-founder. “Grapefruit is laying the groundwork to implement the company’s long-term strategic plans to acquire several retail stores in the eastern part of the United States as the next event in the company’s evolution to a wellness-driven, medical science-based, canna-focused biotech company.”

To view the full press release, visit

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. For more information about the company and its operations, visit

Grapefruit USA Inc. (GPFT), closed Friday's trading session at $0.0026, off by 3.7037%, on 609,679 volume. The average volume for the last 3 months is 1.411M and the stock's 52-week low/high is $0.0025/$0.0348.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent surge in psychedelic research has revealed that psychedelics appear capable of treating mental health conditions such as treatment-resistant depression and post-traumatic stress disorder. Although much of this research is still in its infancy, it is definitive enough that lawmakers in several states, cities and local governments are considering legalizing psychedelic treatments.

Oregon passed a measure allowing psychedelics for mental health treatments last year, and several cities, including Arcata, Ann Arbor, Denver and Detroit have passed legislation to decriminalize psychedelics.  As more states and cities consider decriminalizing psychedelics, insurers and employers may have to start covering psychedelic treatments.

Dr. Bronner’s, a family-owned company that makes natural brands of soap, is among the first companies to begin offering coverage for psychedelic treatments. Company president Michael Bronner announced in early 2022 that the company would start offering ketamine-assisted therapy as a workplace benefit.

The company will partner with Enthea, which provides insurance plans for psychedelic treatments, to facilitate the benefit. After a successful seed round raise, Enthea announced in December 2022 that it would begin offering its services across 40 markets in the United States.

Liz Kost, a Dr. Bonner’s employee, took advantage of the psychedelic workplace benefit and had six sessions as soon as it was offered. She had been struggling with her mental health since the coronavirus pandemic and had seen little relief from traditional forms of therapy. Kost said that the six sessions she went through were much more beneficial compared to traditional therapy.

Unfortunately, Dr. Bronner’s is one of a very few companies that cover psychedelic-assisted therapy for their employees. Even fewer insurers provide coverage for psychedelic therapies. Kost says that she probably would not have paid for the treatment out of pocket if her employer did not offer coverage.

Field Trip, a company that provides ketamine-assisted therapy, says that patients usually see a reduction in anxiety and depression from severe to mild in around four to six sessions. But Field Trip cofounder and CEO Ronan Levy notes that insurers will often cover only the psychotherapy section of the treatment rather than the full treatment, which can cost $4,000 to $6,000.

Enthea CEO Sherry Rais observes that rather than providing comprehensive coverage for psychedelic-assisted therapy, major insurers will sometimes cover certain parts of treatment. Rais said that most employers seem to be held back from covering psychedelic therapy due to a lack of education and providers.

Ketamine is currently the only psychedelic that has been approved by the FDA to treat conditions such as bipolar disorder, PTSD, and major depressive disorder. Magic mushrooms (psilocybin) and MDMA are still in the approval process and are expected to receive FDA approval in the near future.

As enterprises such as Seelos Therapeutics Inc. (NASDAQ: SEEL) advance their R&D programs, more information will become available about the potential benefits and risks of different psychedelics. Such data may go a long way in bringing employers and insurers on board so that employees can access these therapies cost effectively.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.66, up 11.8644%, on 1,410,629 volume. The average volume for the last 3 months is 5.454M and the stock's 52-week low/high is $0.4803/$1.52.

QuantumScape Corp. (QS)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, The Street, MarketBeat, The Online Investor, QualityStocks, StockEarnings, Daily Trade Alert, Top Pros' Top Picks, TipRanks, wyatt research newsletter, Atomic Trades, Trades Of The Day, INO Market Report, Green Energy Stocks, CNBC Breaking News, Cabot Wealth and BUYINS.NET reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Even with the governments stating that by 2030, 50% of total sales of newly purchased cars should be electric vehicles and companies making significant goals for turning mostly electric, there appear to be roadblocks in the way. For instance, both the private and public sectors will need to invest billions of dollars in charging points and batteries, as well as automobiles. A scarcity of charging points, electric vehicle travel range anxiety, and the expense of finding, acquiring, and maintaining the developing machines all contribute to the slowdown in EV adoption.

However, the industry hopes to quickly allay the majority of these concerns since the support needed to reverse this trend is sufficiently available. The engineering of electric vehicles is advancing at a remarkable rate, and the Internet of Things (IoT) capabilities and applications are becoming more widely accessible. IoT features could, in fact, be ready to help remove the majority, if not all, of the obstacles.

Sales of electric vehicles are significantly hampered by travel-range concerns. Several studies reveal that electric vehicles can only go between 250 and 300 miles without another charge, which poses a major issue for prospective purchasers because gas outlets currently outweigh electric vehicle charging points by a wide margin.

The range issue won’t be solved directly by Internet of Things technology, but evolving Internet of Things technologies for vehicle sensing and analytics will support the gathering and sharing of information with motorists and fleet operators to enhance range effectively and provide actual data concerning safety and traffic straight to electric vehicles for guidance along routes. Besides, satellite technology may also be able to pinpoint IoT devices inside electric vehicles centimeters off the actual placements, allowing communication with other vehicle types, drivers and internet connectivity. This ought to enhance cellular access for motorists in outlying places.

Cloud telematics and Internet of Things technologies are currently being used by several fleets for monitoring battery condition and fuel usage as well as keeping an eye on driving habits. Scania Trucks, for example, apparently employs sensors from IoT technology responsible for tracking numerous vehicle details in order to detect concerns associated with the system remotely.

Internet of Things technology may also make it easier for electric vehicle drivers to find and use charging points, particularly ones that use renewable power. In Europe, digitally enabled platforms are emerging to provide electric vehicle motorists with updated details regarding the condition and suitability of nearby charging stations.

Due to the complexity and difficulty of manufacturing electric vehicle components, IoT technology can also assist component producers in shifting their focus away from combustion and emissions and toward computer and battery technology.

The EV industry is seeing rapid growth, and the players therein, such as QuantumScape Corp. (NYSE: QS),  are deploying the latest technology to see to it that consumer expectations are met and that companies corner a section of the market for themselves.

QuantumScape Corp. (QS), closed Friday's trading session at $7.35, up 0.409836%, on 5,454,026 volume. The average volume for the last 3 months is 18.172M and the stock's 52-week low/high is $5.11/$22.21.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Investopedia, TopStockAnalysts, Money Morning, Daily Trade Alert, Zacks, Louis Navellier, VectorVest,, Trading Markets, ProfitableTrading, The Growth Stock Wire, Daily Wealth, QualityStocks, The Wealth Report, Top Pros' Top Picks, The Online Investor, TheStockAdvisors, All about trends, Wall Street Elite, StreetAlerts, TradingMarkets, Leeb's Market Forecast, Trading Tips, Streetwise Reports, Market FN, Dividend Opportunities, Market Report, TheStockAdvisor, Investor Guide, InvestmentHouse, Early Bird, Investors Alley, StockTwits, Trading Concepts, Wealth Insider Alert, Investment House, Options Trader Elite, InvestorGuide, The Best Newsletters, Market Intelligence Center Alert, Money and Markets, INO Market Report, Cabot Wealth, Investing Signal, Energy and Capital, Darwin Investing Network, Buttonwood Research, Wyatt Investment Research, Wealth Daily, Trade of the Week, AnotherWinningTrade, Bourbon and Bayonets, StockEarnings, The Motley Fool, Super Stock Investor, TradingAuthority Daily, Market Authority, Investor Update, Stock Research Newsletter, Wall Street Daily, MarketWatch, Wealthpire Inc., Street Insider, Profit Confidential, Dynamic Wealth Report, InvestorsUnderground, AllPennyStocks, Uncommon Wisdom, WStreet Market Commentary, Daily Markets, DividendStocks, FeedBlitz, CNBC Breaking News, Weekly Wizards, FNNO Newsletters, 24/7 Trader, Normandy Investment Research, TradersPro, Market Intelligence Center, Investment U, Weekly Market Strategies, Insider Wealth Alert, Inside Investing Daily, Investiv, SmallCapVoice, BUYINS.NET, Rick Saddler, Daily Profit, Profits Run, ChartAdvisor, Oakshire Financial, StreetAuthority Investor Update, Stock Barometer, Stockhouse, Pennybuster, The Tycoon Report, Greenbackers, Navellier Growth, Hit and Run Candle Sticks, Average Joe Options, Forbes, Stock Beast,, Trader Prep, The Street Report, The Stock Dork, The Night Owl, The Daily Market Alert, Terry's Tips, Taipan Daily, Super Stock Picker, StreetAuthority Financial, Stocks To Watch, StockRockandRoll, Penny Stock Buzz, StockLockandLoad, Inside Trading, SmallCap Network, Shah's Insights & Indictments, Schaeffer’s, PowerRatings Stocks, Penny Sleuth, Milestone Capital Growth Portfolio, MicroCap Gems, MarketTamer, Jason Bond, Investors Underground, Investors Daily Edge, Investing Daily and StockMarketWatch reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Artisanal gold mining refers to small-scale mining operations that often use basic tools and methods to extract and process metals and minerals. These operations often rely on toxic methods and tools to mine gems and metals, with the miners themselves working in hazardous conditions with little regulation regarding health and environmental pollution standards.

According to planetGold program manager Ludovic Bernaudat, more than 100 million people earn their living from artisanal gold mining. Artisanal gold mines produce up to 20% of all the gold in the world and are responsible for more than 35% of the globe’s mercury pollution.

A 2018 UNEP Global Mercury Assessment estimated that artisanal and small-scale gold mining (ASGM) releases more than 2,000 tons of mercury into the land, air and water every year. planetGold is an initiative led by the UN Environment Programme (UNEP) and funded by the Global Environment Facility. It was launched in 2019, and it aims to cut mercury use by 512 tons, reduce carbon dioxide equivalent emissions by 400,000 tons, and improve more than 1.2 million hectares of land.

Artisanal gold mining is one of the industries this initiative is looking to address because of its rampant use of mercury coupled with hazardous working conditions. An estimated 20 million people across 80 countries are involved in artisanal and small-scale gold mining, with most of them living in rural areas and countries with limited economic opportunity. Over four million women and children are involved in these operations, and they are often exposed to hazardous conditions due to a lack of training and safety equipment coupled with the presence of dangerous chemicals such as mercury.

Mercury is a toxic contaminant that does not degrade in the environment and can build up in the environment before entering the food chain and causing systemic damage to the ecosystem. Denver Suzara, president of a Philippine mining association, says that miners don’t like using mercury, but they simply have no choice.

In East Africa, more than 250,000 young Kenyans have become small-scale gold miners, but these miners struggle to access proper equipment. planetGold is working to eliminate mercury from the gold supply chain in Kenya and more than 20 other countries by raising awareness and providing miners access to financing, technical solutions and formalization.

Given that the ASGM sector is severely undercapitalized, increasing access to financing will allow artisanal and small gold mines to obtain the necessary expertise and proper equipment for the job. Additionally, providing technical solutions, better practices and alternative technologies will reduce the risk of negative impacts on miners’ health and their communities while increasing their take-home.

As more miners join the ranks of established entities such as Freeport-McMoRan Inc. (NYSE: FCX), the use of dangerous substances such as mercury will reduce and safety will drastically improve.

Freeport-McMoRan Inc. (FCX), closed Friday's trading session at $37.88, off by 3.2933%, on 18,172,029 volume. The average volume for the last 3 months is 1,200 and the stock's 52-week low/high is $24.80/$51.99.

The QualityStocks Company Corner

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’srenewable natural gas (“RNG”) infrastructure platform, aims toadvance Canada’s RNG infrastructure by building a network spanning20+ facilities within five years. “The company acquires, develops,builds, owns, and operates a portfolio of RNG waste-to-energy andrelated infrastructure projects on the west coast in BritishColumbia, and toward the east with facilities in Alberta andOntario… EverGen owns and operates five RNG and/or organicprocessing facilities across Canada,” a recent article reads. “RNGis considered environmentally sustainable because it is derivedfrom sources that otherwise would release methane into theatmosphere while decomposing. RNG production can also help increasecrop yields by creating digestate – a nutrient-rich byproduct ofthe agricultural digestion process that can be used as afertilizer. In addition, RNG production from waste does not consumeland or other natural resources and can help protect areas bydiverting waste from landfills. Biogas demand is escalatingsubstantially as governments worldwide shift their focus toward theuse of renewable energy. Increased RNG use by gas utilities isexpected to additionally catalyze growth.”

To view the full article, visit

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2.3486, up 3.6909%, on 1,200 volume. The average volume for the last 3 months is 1.742M and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue lightemergency communication systems, announced that a long-time realestate client has renewed its K5 Autonomous Security Robot (“ASR”)contract for the fifth consecutive year. The announcement reads,“The client’s affectionately named ‘Optimus Crime’ ASR patrols aSan Francisco Bay Area mixed-use parking structure to help protectthe property, visitors and their vehicles. To learn more about howrobots serve commercial real estate and to make properties moredesirable for tenants and guests, read Knightscope’srecommendations for real estate investors/developers here.” To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Friday's trading session at $1.03, up 18.3908%, on 1,741,680 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.00/$.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Last week the Justice Department (DOJ) released an application form for those who were eligible for President Joseph Biden’s masscannabis pardon to complete to prove that they received clemency.Biden issued an executive order in October pardoning thoseconvicted of marijuana possession offenses in violation of federallaw. Although the pardon was automatic, activists have pushedgovernment representatives to create a form that can be used torequest certificates proving coverage. This might be helpful forindividuals whose previous convictions are, for instance, keepingthem from finding employment or housing. Elizabeth Oyer, the pardonattorney, had stated in December that the online applications wouldbe available soon, but regrettably, nothing of the sort happened,and as the months went by, activists’ impatience grew. The launchof this pardon certificate application is a welcome developmentthat advocates and industry actors such as Advanced Container Technologies Inc. (OTC: ACTX) are likely to applaud, given its potential to fix some of thelasting adverse effects of prohibition upon those with minorcannabis convictions on their records.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.35, up 8.6957%, on 4,534 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.25.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

Massachusetts-headquartered cybersecurity services and technologyprovider SideChannel Inc. is building its operational model oncontracting out its employees’ expertise as “virtual” chiefinformation security officers (vCISOs) to companies that can’tafford to staff their own CISOs

SideChannel’s CEO and CFO recently addressed the company’s history,expertise and strategies for the future in an Investor Day webcastthat is now being rebroadcast on the company’s YouTube channel

The webcast noted that SideChannel is tapping into an underservedmarket of mid-market clients whose needs for cybersecurity mirrorthose of larger-budget companies who can afford to employ their ownCISOs

During 2022, about 200,000 cyber attacks were reported at anaverage cost of $4.5 million per company to recover when a breachoccurred, according to the webcast

An Investor Day webcast event hosted by cybersecurity services andtechnology provider SideChannel (OTCQB: SDCH) provided insights on the company in a virtual meeting place thataddressed the company’s history, its products, its financialposition, its strategies for the future and introduced some ofofficers and board members for those investigating SideChannel’spotential.

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.075, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$0.18.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, a MERJ Exchange market, announced that it has recently reached asignificant milestone of 5,000 users and counting that have joinedits trading community. The achievement comes on the heels ofUpstream’s welcoming of multiple dual-listing issuers since thebeginning of the year, as well as success with its digital couponNFT strategy and trading hub. “We’re thrilled with the progresswe’ve made in recent months; with the addition of threedual-listing issuers and successful NFT campaigns, we’ve reachedour 5k user milestone. We’re excited to continue our goal ofwelcoming the future of trading,” states the Upstream Team.“Upstream is actively accepting dual-listing applications fromNASDAQ, NYSE, OTC Markets and international issuers that areseeking to offer their shares to a modern-day investor pool thataccepts USDC cryptocurrency and traditional payments.” To view thefull announcement, visit

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

The global antihypertensive drugs market was valued at around $20.5billion in 2021 and is expected to reach $39.5 billion by 2030,growing at a CAGR of 2.95%

Lexaria’s patented DehydraTECH(TM) technology is designed toformulate and deliver lipophilic drugs and active pharmaceuticalingredients (“APIs”), increasing effectiveness and improving howdrugs are delivered into the bloodstream

DehydraTECH is suitable for use with a wide range of productformats, including pharmaceuticals, nutraceuticals, andover-the-counter capsules, pills, tablets, or oral suspensions

Lexaria is continuing to evaluate the results of its HYPER-H21-4human clinical study and will report additional findings as theybecome available

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announcedadditional findings from its human clinical study HYPER-H21-4,demonstrating a potentially novel mechanism of action of itspatented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsuleformulation in reducing blood pressure. The FDA lays out clearguidelines for sponsors seeking to develop new anti-hypertensiondrugs, specifically defining the need for medications that offercomplimentary modes of action. Lexaria believes that its latestresults, detailed in the peer-reviewed and published in thejournal “Biomedicine and Pharmacotherapy," may supportDehydraTECH-CBD qualification within the FDA guidelines (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.94, off by 7.5384%, on 56,846 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals Inc. (INM) among companies presented byVirtual Investor Conferences, the leading proprietary investorconference series, which has announced the presentations from theLife Sciences Virtual Investor Forum held on March 9th are nowavailable for online viewing.REGISTER NOW AT :

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Friday's trading session at $1.05, off by 0.943396%, on 77,848 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.9213/$35.50.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is engaged in the exploration for and separation and scalableproduction of rare earth elements (“REEs”) in Canada and the U.S.The company is disrupting China’s dominance with its near-termprocessing facility in Louisiana, subsequent Strategic MetalsComplexes (“SMCs”) in Alaska and Canada, and longer-termdevelopment of Boken Mountain on Prince of Wales Island, Alaska.This comes as current tensions between the U.S. and China havebrought to light the urgency for North America to have its own REEprocessing alternatives. “Ucore’s RapidSX(TM) technology providesadditional industry options for overcoming the dominance of Chinain processing REEs through its development of near-term andlong-term processing facilities in North America,” a recent articlereads. “The processing facilities will incorporate Ucore’sRapidSX(TM) technology, which combines the time-proven chemistry ofconventional solvent extraction (‘SX’) with a new column-basedplatform that significantly reduces time to completion and plantfootprint, as well as potentially lowering capital and operatingcosts. SX is currently the international REE industry’s standardcommercial separation technology for bulk separation of heavy andlight REEs. The commissioning process of Ucore’s RapidSX(TM)Demonstration Plant is underway in Kingston, Ontario.”

To view the full article, visit

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is engaged in Rare Earth Element (REE) resource development and in commercializing its critical metals separation technology, RapidSX™, for the mining and metals extraction industry. The company is guided by principles of environmental, social and corporate governance (ESG) with a focus on disrupting China’s current dominance of the U.S. REE supply chain.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. It plans to aid in the development, through strategic partnerships, of a North American REE supply chain controlled by the U.S. and its allies.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Friday's trading session at $0.9253, off by 1.331%, on 10,194 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.40/$1.15.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software, and services,and the only quantum computing company building commercialannealing quantum computing systems and developing gate-modelquantum computing systems, has announced the date that it plans onreleasing its financial results for Q4 2022. The company willrelease the fourth-quarter financial report before the market openson March 30, 2023. The company also noted that the financial reportwill include numbers for the full 2022 fiscal year. In addition,the company noted that it will host a conference call at 8 a.m. ETon the same day, when D-Wave Quantum CEO Alan Baratz and CFO JohnMarkovich will discuss the financial results as well as present anoutlook for the business. Those interested can join by dialing1-877-407-3982 (domestic) or 201-493-6780 (international) and thenusing the conference ID code 13736952. A replay of the call willalso be available on the company website following the conclusionof the call. To view the full press release, visit

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $0.6226, off by 8.4412%, on 853,228 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.62/$13.23.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

Cerberus Cyber Sentinel (NASDAQ: CISO) is an industry leader as a global cybersecurity and complianceprovider. The company is rapidly expanding by acquiring world-classcybersecurity, secured managed services, and compliance companieswith top-tier talent that utilize the latest technology to createinnovative solutions to protect the most demanding businesses andgovernment organizations, mitigating continuing and emergingsecurity threats and compliance obligations. Cerberus operatesmultiple fully staffed, 24x7x365 security operations centers on twocontinents, from which it monitors core infrastructure andorganizations essential to a stable global economy. Supportingend-to-end cybersecurity and compliance, the company specializes inregulated industries. Cerberus maintains a presence in NorthAmerica, Latin America, and Europe. For more information, visit thecompany’s website at To schedule a one-on-one meeting, please contact your ROTH MKMrepresentative. To view IBN’s coverage of the conference, visit

CISO Global Inc. (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., an industry leader inmanaged cybersecurity and compliance services, recently rebrandedand changed its company logo to reflect its global footprint andgrowth. This comes as cybersecurity increases in importance intoday’s digital world and is top priority for savvy businesses. “Inthe past few years, the company has experienced impressive growthon three continents: North America, South America and Europe. Withthe current upward trend and future growth in mind, companyofficials decided that creating a strong parent brand in themarketplace was essential while ensuring the new identity matchesthe global enterprise the company is actively becoming,” a recentarticle reads. CISO Global founder and CEO David Jemmett is quotedas saying: “We have assembled a world-class leadership team, and wehave successfully brought together 16 organizations globally. It istime for our name to reflect who we are as an organization.” AshleyDevoto, the company’s president and chief information securityofficer, is also quoted saying: “The distributed nature ofcybersecurity requires global capabilities to properly address thedemands and complexities of today’s business environment… We are ona mission to demystify and accelerate our clients’ journey to cyberresilience, empowering organizations to securely grow, operate andinnovate.”

To view the full article, visit

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Researchers have found that physicians can predict the future risk of eczema in children via simple skin swabs. Their findings show thatcollecting cells from the top layers of a week-old baby’s skinusing sticky strips can allow doctors to predict whether the infantwill develop eczema. Atopic dermatitis (AD) is the most common typeof eczema. It is characterized by itchy, dry and inflamed skin. While it canoccur at any age, the condition is very common in young children.The condition also increases a patient’s risk of developing asthma,hay fever and food allergies. It affects close to 30% of childrenacross the globe and can have a significant impact on the quality of life ofaffected people and their families. For individuals who are alreadyexperiencing atopic dermatitis, the future may be brighter asentities such as Jupiter Wellness Inc. (NASDAQ: JUPW) finalize and bring to market the superior topical treatments thatthey have been developing.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is beingtested for the first time ever on humans in an FDA-approved study.This is groundbreaking work that established its commitment as apioneer in the treatment of Alzheimer’s disease, given there are nocurrently FDA-approved drugs to treat Alzheimer’s patients. “Thecompany is developing its proprietary treatment, IGC-AD1, hoping toprovide relief to the 55 million people worldwide struggling withagitation in dementia that results from Alzheimer’s. IGC is focusedon revolutionizing the treatment of Alzheimer’s with itsgame-changing drug candidate. In phase 1 studies, IGC-AD1 showspotential to safely reduce the debilitating symptoms that impactmillions of Alzheimer’s patients and their caregivers. Featuring alow dose of THC, the treatment is the first natural cannabis-basedinvestigational drug being tested in human FDA trials to treatAlzheimer’s patients; it provides medical benefits withoutpsychoactive effects. ‘As millions of Alzheimer’s patients continueto suffer from agitation, anxiety and depression, phase 2 clinicaltrials bring hope for a treatment,’ the company reports.” To viewthe full article, visit

Despite dozens of states legalizing cannabis use for either medicalor recreational purposes, America’s illicit cannabis market isstill going strong. Legal operators have struggled to compete withillicit sellers amid strict regulations and relatively high cannabis taxes that have made legal marijuana much more expensive than its illicit counterpart. By the end of 2021, illicit sales ofcannabis had reached close to $8 billion annually, doubling the volume of sales from legal operators and forcingmany of them to close shop. However, in California regulators areactively taking steps to reduce the illicit market’s strangleholdon the state’s cannabis industry. No such light punishments existfor entities operating within the purview of the FDA, which is whyfor-profit companies such as India Globalization Capital Inc. (NYSE American: IGC) are taking their product pipeline through a meticulous preclinicaland clinical development process so that once the THC-basedformulations are approved, no questions will arise about theirefficacy or safety profile.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.369899, off by 1.8836%, on 174,588 volume. The average volume for the last 3 months is 174,588 and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.